Aadi Bioscience amends supply agreement with Fresenius Kabi for Fyarro; term extended to March 2024

Whitehawk Therapeutics, Inc.

Amendment extends contract term to March 31, 2024 (or later date if agreed).
Pricing and minimum purchase quantity obligations for Fyarro were updated and revised.
Agreement covers clinical and commercial manufacturing of Fyarro (sirolimus albumin-bound).
Contains customary biotech manufacturing terms; full agreement to be filed later.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Whitehawk Therapeutics, Inc. amended Amendment No.1 with Fresenius Kabi, LLC (effective 2023-01-17).

Action: amendment
Agreement: supply
Counterparty: Fresenius Kabi, LLC
Effective: 2023-01-17

Exact text from the filing

On January 17, 2023, Aadi Bioscience, Inc. (the “ Company ”) entered into Amendment No.1 (the “ Amendment ”) to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the “ Agreement ”) with Fresenius Kabi, LLC (“ Fresenius Kabi ”).

View on SEC.gov

152 material agreements filed in the last 30 days. Browse all material agreements →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-012507

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.